Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Garvey, W. Timothy, Blüher, Matthias, Osorto Contreras, Cynthia Karenina, Davies, Melanie J., Winning Lehmann, Eva, Pietiläinen, Kirsi H., Rubino, Domenica, Sbraccia, Paolo, Wadden, Thomas, Zeuthen, Niels, Wilding, John P.H.·2025·New England Journal of Medicine

Abstract

In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. Participants were randomly assigned to receive the combination of semaglutide 2.4 mg and cagrilintide 2.4 mg (CagriSema) or placebo. The estimated mean change in body weight from baseline to week 68 was -20.4% with CagriSema compared to -3.0% with placebo. Gastrointestinal adverse events occurred in 79.6% in the CagriSema group vs 39.9% in the placebo group.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2502081

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 32 references

Cited by

See all 238

Metadata

Authors
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. H.
Affiliations
  • University of Alabama at Birmingham (US)
  • Helmholtz Munich (DE)
  • Novo Nordisk, Søborg, Denmark
  • University of Leicester (GB)
  • University of Helsinki (FI)
  • Washington Center for Weight Management and Research (US)
  • University of Rome Tor Vergata (IT)
  • University of Pennsylvania (US)
  • Novo Nordisk (Denmark) (DK)
  • University of Liverpool (GB)
Venue
New England Journal of Medicine
Published
2025-08-14
Volume
393
Issue
7
Pages
635-647
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4411522078
Cited by
238
References
32
Citations by year
2026: 181 · 2025: 57
FWCI
133.58
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
cagrilintide, semaglutide, combination therapy, obesity, overweight, weight loss, GLP-1 receptor agonists, GIP receptor agonist, obesity-related comorbidities, lifestyle intervention, treatment policy estimand, cardiovascular outcomes, GIP/GLP-1 receptor agonist
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Hypertension, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Dyslipidemias, Overweight, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. https://app.cochat.ai/papers/10.1056/nejmoa2502081
The paper
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. H. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2502081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.